International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 3 , Pages 696-702 , 1 November 2009

Basic Fibroblast Growth Factor-2/β3 Integrin Expression Profile: Signature of Local Progression After Chemoradiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer

  • Carole Massabeau, M.D.

      Affiliations

    • Département de Radiothérapie, Institut Claudius Regaud, Toulouse, France
    • ,
  • Isabelle Rouquette, M.D.

      Affiliations

    • Service d'Anatomie Pathologique et Histologie-Cytologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
    • ,
  • Valérie Lauwers-Cances, M.D.

      Affiliations

    • Service d'Epidémiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
    • ,
  • Julien Mazières, M.D., Ph.D.

      Affiliations

    • Service de Pneumologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Toulouse, France
    • ,
  • Jean-Marc Bachaud, M.D.

      Affiliations

    • Département de Radiothérapie, Institut Claudius Regaud, Toulouse, France
    • ,
  • Jean-Pierre Armand, M.D.

      Affiliations

    • Département d'Oncologie, Institut Claudius Regaud, Toulouse, France
    • ,
  • Marie-Bernadette Delisle, M.D.

      Affiliations

    • Service d'Anatomie Pathologique et Histologie-Cytologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
    • ,
  • Gilles Favre, Ph.D.

      Affiliations

    • INSERM U563, Institut Claudius Regaud, Toulouse, France
    • ,
  • Christine Toulas, Ph.D.

      Affiliations

    • INSERM U563, Institut Claudius Regaud, Toulouse, France
    • ,
  • Elizabeth Cohen-Jonathan-Moyal, M.D., PhD.

      Affiliations

    • Département de Radiothérapie, Institut Claudius Regaud, Toulouse, France
    • INSERM U563, Institut Claudius Regaud, Toulouse, France
    • Corresponding Author InformationReprint requests to: Elizabeth Cohen-Jonathan-Moyal, M.D., Ph.D., Département de Radiothérapie, Institut Claudius Regaud, 20-24 rue du Pont St. Pierre, Toulouse 31052 Cedex France. Tel: (33) 56-142-4178; Fax: (33) 56-142-4643

Received 4 August 2008 ,Revised 19 November 2008 ,Accepted 21 November 2008.

References 

  1. Jett JR, Scott WJ, Rivera MP, et al. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 2003;123:221S–225S
  2. Curran WJ. Evolving chemoradiation treatment strategies for locally advanced non–small-cell lung cancer. Oncology (Williston Park). 2003;17:7–14
  3. Vokes EE, Herndon JE, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non–small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol. 2002;20:4191–4198
  4. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non–small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study. J Clin Oncol. 2005;23:5910–5917
  5. Kim S, Kim M, Choi E, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): Randomized phase III trial. J Clin Oncol. 2007;25:7528
  6. Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol. 2007;25:7512
  7. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8–31
  8. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–991
  9. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res. 2007;13:994–999
  10. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol. 2006;24:4731–4737
  11. Milas L, Mason KA, Ang KK. Epidermal growth factor receptor and its inhibition in radiotherapy: In vivo findings. Int J Radiat Biol. 2003;79:539–545
  12. Schmidt-Ullrich RK, Contessa JN, Lammering G, et al. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene. 2003;22:5855–5865
  13. Fuks Z, Persaud RS, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994;54:2582–2590
  14. Delmas C, Heliez C, Cohen-Jonathan E, et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer. 2002;100:43–48
  15. Ader I, Toulas C, Dalenc F, et al. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene. 2002;21:5998–6006
  16. Cohen-Jonathan E, Toulas C, Monteil S, et al. Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res. 1997;57:1364–1370
  17. Shah L, Walter KL, Borczuk AC, et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer. 2004;101:1632–1638
  18. Ader I, Muller C, Bonnet J, et al. The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene. 2002;21:6471–6479
  19. Ader I, Delmas C, Bonnet J, et al. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene. 2003;22:8861–8869
  20. Skuli N, Monferran S, Delmas C, et al. Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res. 2006;66:482–489
  21. Skuli N, Monferran S, Delmas C, et al. alphavbeta3/alphavbeta5 integrins-FAK-RhoB: A novel pathway for hypoxia regulation in glioblastoma. Cancer Res. 2009;69:3308–3316
  22. Takanami I, Tanaka F, Hashizume T, et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: An investigation of their expression as prognostic markers. Eur J Cancer. 1996;32A:1504–1509
  23. Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002;62:7124–7129
  24. Kuhn H, Konrad J, Holtz S, et al. Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. Lung Cancer. 2006;54:149–153
  25. Monferran S, Skuli N, Delmas C, et al. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer. 2008;123:357–364
  26. Albert JM, Cao C, Geng L, et al. Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non–small-cell lung cancer models. Int J Radiat Oncol Biol Phys. 2006;65:1536–1543
  27. Senan S, De Ruysscher D, Giraud P, et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol. 2004;71:139–146
  28. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005;40:90–97
  29. Zhou XH, Obuchowski NA, McClish DK. Sample size calculation. In:  Balding DJ,  Bloomfield P,  Cressie NAC editor. Statistical methods in diagnosis medicine. New York: John Wiley & Sons; 2002;p. 195–221
  30. Gruber G, Hess J, Stiefel C, et al. Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br J Cancer. 2005;92:41–46
  31. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. Blood. 2004;104:3635–3641
  32. Volm M, Koomagi R, Mattern J, et al. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer. 1997;33:691–693
  33. Anttonen A, Heikkila P, Kajanti M, et al. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer. 2001;32:297–305
  34. Toyoshima E, Ohsaki Y, Nishigaki Y, et al. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. Lung Cancer. 2001;31:193–202
  35. Sloan EK, Pouliot N, Stanley KL, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006;8:R20
  36. Hieken TJ, Ronan SG, Farolan M, et al. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer. 1999;85:375–382
  37. Duensing S, Grosse J, Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res. 1995;15:2331–2333
  38. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–1159
  39. Delmas C, End D, Rochaix P, et al. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res. 2003;9:6062–6068

 Supported by the Groupe de Recherche de l'Institut Claudius Regaud and the Institut National de la Santé et de la Recherche Médicale.

 Presented at the French Society of Radiation Oncology (SFRO), Paris, 2007.

 Conflict of interest: none.

PII: S0360-3016(08)03836-4

doi: 10.1016/j.ijrobp.2008.11.050

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 3 , Pages 696-702 , 1 November 2009

Article Tools

* Image Usage & Resolution